LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 12,371 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 12,371 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $7.00, for a total value of $86,597.00. Following the completion of the transaction, the director owned 1,375,989 shares in the company, valued at $9,631,923. This trade represents a 0.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Robert Bessler also recently made the following trade(s):

• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Stock Down 0.6%

Shares of LifeStance Health Group stock opened at $6.88 on Wednesday. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -229.33 and a beta of 1.13. The stock has a 50-day simple moving average of $5.90 and a 200-day simple moving average of $5.34. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. The company had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share. On average, equities research analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LFST. Vanguard Group Inc. boosted its position in shares of LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after acquiring an additional 2,383,728 shares during the period. Dimensional Fund Advisors LP raised its stake in LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the last quarter. Wellington Management Group LLP boosted its holdings in LifeStance Health Group by 2.3% in the 1st quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company’s stock valued at $35,959,000 after purchasing an additional 123,056 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after purchasing an additional 1,839,465 shares during the period. Finally, Barclays PLC grew its position in LifeStance Health Group by 74.7% in the 3rd quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after purchasing an additional 1,499,687 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

LFST has been the topic of several recent research reports. Wall Street Zen lowered LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. BTIG Research raised their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, December 12th. BMO Capital Markets started coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price for the company. UBS Group increased their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.83.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.